UK markets closed

Vertex Pharmaceuticals Incorporated (VRTX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
420.43+1.61 (+0.38%)
As of 03:39PM EDT. Market open.
Show:
Income statement
Balance sheet
Annual

Cash flow

All numbers in thousands
Breakdown
ttm
31/12/2023
31/12/2022
31/12/2021
31/12/2020
Cash flows from operating activities
Net income
4,019,400
3,619,600
3,322,000
2,342,100
2,711,700
Depreciation & amortisation
196,000
181,300
148,300
125,600
109,500
Deferred income taxes
-581,400
-536,500
-275,900
-154,600
277,300
Stock-based compensation
650,700
581,200
491,300
441,400
429,500
Change in working capital
-275,300
-265,700
340,800
-105,200
-54,400
Accounts receivable
-245,200
-84,100
-358,600
-274,700
-223,400
Inventory
-320,400
-322,900
-136,400
-92,800
-132,000
Accounts payable
13,100
48,700
120,800
31,900
51,300
Other working capital
3,479,300
3,278,900
3,925,200
2,408,500
2,993,700
Other non-cash items
-99,400
-43,200
-45,700
11,300
91,800
Net cash provided by operating activities
3,944,000
3,537,300
4,129,900
2,643,500
3,253,500
Cash flows from investing activities
Investments in property, plant and equipment
-464,700
-258,400
-204,700
-235,000
-259,800
Acquisitions, net
-
0
-295,900
0
0
Purchases of investments
-4,574,500
-3,817,500
-740,500
-605,200
-450,700
Sales/maturities of investments
1,594,700
934,200
920,000
499,300
809,900
Net cash used for investing activities
-3,444,500
-3,141,700
-321,100
-340,900
99,400
Cash flows from financing activities
Debt repayment
-47,500
-44,900
-85,500
-47,000
-42,300
Common stock repurchased
-719,000
-653,700
-172,000
-1,561,300
-739,400
Other financing activities
-
-
3,500
5,700
-1,800
Net cash used provided by (used for) financing activities
-625,000
-562,200
-67,700
-1,478,000
-505,300
Net change in cash
-126,200
-139,700
3,711,900
811,200
2,868,200
Cash at beginning of period
9,295,600
10,512,000
6,800,100
5,988,900
3,120,700
Cash at end of period
9,170,100
10,372,300
10,512,000
6,800,100
5,988,900
Free cash flow
Operating cash flow
3,944,000
3,537,300
4,129,900
2,643,500
3,253,500
Capital expenditure
-464,700
-258,400
-204,700
-235,000
-259,800
Free cash flow
3,479,300
3,278,900
3,925,200
2,408,500
2,993,700